Boardroom Alpha
Boardroom Alpha
CING · Current Report (Form 8-K) · Filed July 14, 2026

Cingulate Inc — Current Report (Form 8-K)

Form
8-K
Filed
July 14, 2026
Period
Jul 9, 2026
Ticker
CING
Accession
0001493152-26-033115
Boardroom Alpha · Filing insights

Stockholders approve Amendment No. 3 increasing equity-plan shares by 625,000; board size cut to five; CEO Schaffer chair.

About Cingulate Inc
Market cap
$85M
1Y TSR
+18.2%
3Y TSR
−67.4%
Board grade
C-
Sector
Healthcare
CEO
Jennifer L Callahan
Last annual meeting: Jul 9, 2026 · View full Cingulate Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 9, 2026

 

CINGULATE INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40874   86-3825535
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

1901 W. 47th Place

Kansas City, KS 66205

(Address of principal executive offices) (Zip Code)

 

(913) 942-2300

(Registrant’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
   

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.0001 per share   CING  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

Warrants, exercisable for common stock   CINGW  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Equity Plan Amendment

 

At the Cingulate Inc. (the “Company”) 2026 Annual Meeting of Stockholders held on July 9, 2026 (the “Annual Meeting”), the Company’s stockholders approved Amendment No. 3 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan (the “Equity Plan”) to increase the number of shares of common stock authorized for issuance thereunder by 625,000 shares (the “Amendment”). The board of directors of the Company had previously approved the Amendment, subject to stockholder approval, and the Amendment became effective upon such stockholder approval.

 

A copy of the Amendment is included with this Form 8-K as Exhibit 10.1 and is incorporated herein by reference, and the foregoing summary is qualified in its entirety by reference to the terms and provisions of the Amendment.

 

Changes to Board Structure

 

On the date of the Annual Meeting, the Company’s Board of Directors (the “Board”) reduced the size of the Board to five (5) directors and appointed Shane Schaffer, the Company’s Chief Executive Officer, as the chairman of the Board. The Board appointed Jeff Hargroves as the lead independent director of the Board.

 

The Board also appointed Zhanpeng “Frederick” Jiang as the chairman of the Audit Committee of the Board and Mr. Hargroves as the chairman of the Nominating and Corporate Governance Committee of the Board. Following the Annual Meeting: (i) the Audit Committee of the Board consists of Mr. Jiang , as chairman, Mr. Hargroves and Bryan Lawrence, (ii) the Nominating and Corporate Governance Committee of the Board consists of Mr. Hargroves, as chairman, Mr. Jiang and Mr. Lawrence and (iii) the Compensation Committee of the Board consists of Mr. Lawrence, as chairman, Mr. Hargroves and Mr. Jiang.

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

At the Annual Meeting, four proposals were submitted to the Company’s stockholders. The final voting results were as follows:

 

Proposal 1

 

The Company’s stockholders elected the following Class II director to serve for a term expiring at the 2029 annual meeting of stockholders and until his successor has been duly elected.

 

Name  For  Withhold  Broker Non-Votes
Jeff Hargroves   3,563,369    40,558    4,672,130 

 

 

 

 

Proposal 2

 

The Company’s stockholders approved the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.

 

For  Against  Abstain  Broker Non-Votes
 8,153,858    100,881    21,318    0 

 

Proposal 3

 

The Company’s stockholders approved the Amendment to the Equity Plan to increase the number of shares of common stock authorized for issuance thereunder by 625,000 shares to 2,221,126 shares.

 

For  Against  Abstain  Broker Non-Votes
 3,196,215    372,123    35,589    4,672,130 

 

Proposal 4

 

The Company’s stockholders approved the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of one or more of foregoing proposals. Adjournment of the Annual Meeting was deemed not necessary, because there were sufficient votes at the time of the Annual Meeting to approve each proposal.

 

For  Against  Abstain  Broker Non-Votes
 7,563,297    663,663    49,097    0 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
10.1   Amendment No. 3 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CINGULATE INC.
     
Dated: July 14, 2026 By: /s/ Shane J. Schaffer
  Name:  Shane J. Schaffer
  Title: Chief Executive Officer

 

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Cingulate Inc (CING)

Reference

Frequently asked questions

When did Cingulate Inc file this 8-K?
Cingulate Inc (CING) filed this Current Report (Form 8-K) with the SEC on July 14, 2026. The accession number assigned by EDGAR is 0001493152-26-033115.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Stockholders approve Amendment No. 3 increasing equity-plan shares by 625,000; board size cut to five; CEO Schaffer chair. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Cingulate Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Cingulate Inc has filed under CIK 1862150, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer